[Maintenance treatment and early intervention--the new paradigm in the management of atopic eczema].
Korting
Hans Christian
HC
Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München. H.C.Korting@lrz.uni-muenchen.de
D000287:Administration, Topical; D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D019091:Critical Pathways; D003430:Cross-Sectional Studies; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D042241:Early Diagnosis; D000068298:Fluticasone; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D007223:Infant; D008134:Long-Term Care; D012008:Recurrence; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
D000730:Androstadienes; D065095:Calcineurin Inhibitors; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D000068298:Fluticasone; D016559:Tacrolimus